US clinical trials: devices industry forearms on disclosure issue
This article was originally published in Clinica
The US device industry is bracing itself for the possibility that it could be caught up in the fall-out of the growing controversy over whether pharmaceutical companies are fully disclosing details of their clinical trials.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.